<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03246542</url>
  </required_header>
  <id_info>
    <org_study_id>AAMABDELKADER 4</org_study_id>
    <nct_id>NCT03246542</nct_id>
  </id_info>
  <brief_title>Promising Bimarker Prediction of Outcome of HELLP Syndrome.</brief_title>
  <official_title>Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AYMAN ABDELKADER MOHAMED ABDELKADER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams Maternity Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HELLP syndrome is a life-threatening obstetric complication usually considered to be a&#xD;
      variant or complication of pre-eclampsia. And may occasionally be confused with other&#xD;
      diseases complicating pregnancy such as acute fatty liver of pregnancy, gastroenteritis,&#xD;
      hepatitis, appendicitis, gallbladder disease, immune thrombocytopenia, lupus flare,&#xD;
      antiphospholipid syndrome, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura,&#xD;
      and nonalcoholic fatty liver disease. The distinction between thrombotic thrombocytopenic&#xD;
      purpura-hemolytic uremic syndrome and severe preeclampsia is important for therapeutic and&#xD;
      prognostic reasons. However, the clinical and histological features are so similar that&#xD;
      establishing the correct diagnosis is often difficult; furthermore, these disorders may occur&#xD;
      concurrently.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When TTP/HUS does occur during pregnancy, they often are confused initially with obstetric&#xD;
      diagnoses such as severe preeclampsia; hemolysis, elevated liver enzymes and low platelets&#xD;
      (HELLP) syndrome; acute fatty liver of pregnancy; eclampsia, and antiphospholipid antibody&#xD;
      syndrome. This might be related to the fact that the disease entity is rare and often is&#xD;
      unexpected. Nevertheless, a delay in diagnosis of TTP/HUS may result in life-threatening&#xD;
      maternal and fetal consequences. Aim of the current study was to compare the quantitative&#xD;
      assessment of schistocytes in peripheral blood smear between women initially diagnosed as&#xD;
      HELLP syndrome who showed no spontaneous resolution within 48 hrs after delivery and those&#xD;
      who showed spontaneous resolution within 48 hrs after delivery which may help in decreasing&#xD;
      the maternal mortality rate .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">June 1, 2016</completion_date>
  <primary_completion_date type="Actual">December 1, 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Days</target_duration>
  <primary_outcome>
    <measure>laboratory changes after 48 hours of delivery</measure>
    <time_frame>48 hours</time_frame>
    <description>full blood count, liver function tests( AST, ALT, Bilirubin), kidney function (serum creatinine level), coagulation profile (INR, PTT, PT)</description>
  </primary_outcome>
  <enrollment type="Actual">100</enrollment>
  <condition>Pre-Eclampsia, Severe</condition>
  <condition>HELLP Syndrome</condition>
  <condition>Microangiopathy</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>shistocytes percentage</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 100 women with an initial diagnosis of HELLP syndrome were recruited in the&#xD;
        study.&#xD;
&#xD;
        Blood sample taken within 12hrs peripartum and patients followed up 48hrs after delivery&#xD;
        and subdivided in to 2 groups according to improvement or deterioration after 48hrs after&#xD;
        delivery .&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age more than 20 weeks.&#xD;
&#xD;
          -  Age from18 to 40 years old.&#xD;
&#xD;
          -  Fulfilled criteria for the diagnosis of severe preeclampsia.&#xD;
&#xD;
          -  Fulfilled criteria for the diagnosis of HELLP syndrome.&#xD;
&#xD;
        Diagnostic criteria for severe preeclampsia(one of the following):&#xD;
&#xD;
          -  Blood pressure of 160 mm Hg systolic or higher or 110 mm Hg diastolic or higher on two&#xD;
             occasions at least 6 hours apart while the patient is on bed rest (unless&#xD;
             antihypertensive therapy is intiated befor this time).&#xD;
&#xD;
          -  New onest Cerebral or visual disturbances.&#xD;
&#xD;
          -  Pulmonary edema or cyanosis.&#xD;
&#xD;
          -  Sever persistant epigastric or right upper-quadrant pain unresponsive to medication&#xD;
             and not accounted for by alternative diagnosis, or both.&#xD;
&#xD;
          -  Impaired liver function as indicated by abnormally elevated blood concentration of&#xD;
             liver enzymes (to twic normal concentration).&#xD;
&#xD;
          -  Thrombocytopenia (platlet count less than 100, 000 per microliter.&#xD;
&#xD;
        Diagnostic criteria for HELLP syndrome:&#xD;
&#xD;
          -  Hemolysis documented by an increased LDH level and progressive anemia .&#xD;
&#xD;
          -  Hepatic dysfunction documented by an LDH level &gt;600 IU/L, elevated liver enzymes&#xD;
             documented by AST &gt;40 IU/L, ALT&gt;40 IU/L, or both .&#xD;
&#xD;
          -  Thrombocytopenia documented by a platelet nadir less than 150, 000 cells/mm³.&#xD;
             Thrombocytopenia is subclassified as class one HELLP syndrome: platelet nadir ≤50, 000&#xD;
             cells/mm³, class two HELLP syndrome: platelet nadir ≤100, 000 cells/mm³, or class&#xD;
             three HELLP syndrome: platelet nadir ≤150, 000 cells/mm³..&#xD;
&#xD;
        Anticepation of Microangiopathic Hemolytic Anemia:&#xD;
&#xD;
        Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome should be considered in all&#xD;
        pregnant women with severe thrombocytopenia, severe anemia, and elevated lactate&#xD;
        dehydrogenase enzyme.&#xD;
&#xD;
        Exclusion Criteria: any non included criteria&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 23, 2017</study_first_submitted>
  <study_first_submitted_qc>August 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 11, 2017</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams Maternity Hospital</investigator_affiliation>
    <investigator_full_name>AYMAN ABDELKADER MOHAMED ABDELKADER</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>HELLP Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 1, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03246542/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03246542/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

